ImmunityBio Files 8-K: Financial Statements and Exhibits

TL;DR

IBIO filed an 8-K with financial statements and exhibits. Standard disclosure.

AI Summary

On December 10, 2024, ImmunityBio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine disclosure rather than a specific event. No new material financial information or significant corporate actions were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for ImmunityBio, Inc., providing necessary financial statements and exhibits to the SEC. Investors should review the full filing for detailed financial health and operational insights.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate or significant new risks.

Key Players & Entities

• ImmunityBio, Inc. (company) — Registrant
• December 10, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-37507 (other) — Commission File Number
• 43-1979754 (other) — IRS Employer Identification No.
• 3530 John Hopkins Court (address) — Principal executive offices street
• San Diego (location) — Principal executive offices city
• California (location) — Principal executive offices state
• 92121 (zip_code) — Principal executive offices zip code
• (844) 696-5235 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX Nasdaq Global Select
• $200.0 million — ert all principal of the September 2023 $200.0 million promissory note into 103,359,173 shares
• $30.0 million — convert all principal of the March 2023 $30.0 million promissory note into 13,157,894 shares,
• $505.0 million — eld by Nant Capital into a consolidated $505.0 million note (the "Consolidated Note" and such
• $50.0 million — ar event). The holder can request up to $50.0 million of the outstanding principal amount and

Filing Documents

• d883742d8k.htm (8-K) — 58KB
• d883742dex991.htm (EX-99.1) — 11KB
• g883742g35s84.jpg (GRAPHIC) — 32KB
• g883742g97a68.jpg (GRAPHIC) — 126KB
• 0001193125-24-274438.txt ( ) — 559KB
• ibrx-20241210.xsd (EX-101.SCH) — 3KB
• ibrx-20241210_lab.xml (EX-101.LAB) — 17KB
• ibrx-20241210_pre.xml (EX-101.PRE) — 11KB
• d883742d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Investors should review the risks and uncertainties contained in our filings with the Securities and Exchange Commission ("SEC"), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking -5- information presented in this Current Report on Form 8-K is not a guarantee of future events, and that actual events may differ materially from those described in or suggested by the forward-looking information contained in this Current Report on Form 8-K. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other similar terminology. Any forward-looking information presented herein is made only as of the date of this Current Report on Form 8-K, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release dated December 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -6-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Date: December 10, 2024 By: /s/ David Sachs David Sachs Chief Financial Officer -7-

View Full Filing

View this 8-K filing on SEC EDGAR